Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Uppsala University
With
Uppsala University Hospital
Karolinska University Hospital
AFA Insurance
Swedish Cancer Society
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed or refractory CD19+ B-cell lymphoma or leukemia.
Measurable disease.
Performance status ECOG 0-2.
\>18 years old.
Fertile females/males must consent to use contraceptives during participation of the trial.
Signed informed consent.
You may not be if
Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures.
Patients with primary CNS lymphoma.
Known human immunodeficiency virus (HIV) infection.
Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection).
Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the patient.
Treatment with an investigational product within 30 days prior to enrollment, or at least 5 half lives of that drug, which is longest.
Patients that do not consent to that tissue and blood samples are stored in a biobank.
Pregnancy
Clareo Health | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
